Poltreg S.A. (PTG.WA)
PLN 36.0
(4.35%)
PLN 36.0
(4.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.58 Million PLN | 77.77% |
| 2022 | 22.26 Million PLN | 263.93% |
| 2021 | 6.11 Million PLN | 79.41% |
| 2020 | 3.41 Million PLN | -50.23% |
| 2019 | 6.85 Million PLN | -29.37% |
| 2018 | 9.7 Million PLN | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 32.99 Million PLN | -2.47% |
| 2024 Q1 | 33.83 Million PLN | -14.52% |
| 2023 Q1 | 28.88 Million PLN | 29.71% |
| 2023 FY | 39.58 Million PLN | 77.77% |
| 2023 Q2 | 25.97 Million PLN | -10.08% |
| 2023 Q4 | 39.58 Million PLN | -5.63% |
| 2023 Q3 | 41.94 Million PLN | 61.5% |
| 2022 Q2 | 10.74 Million PLN | 23.27% |
| 2022 Q1 | 8.71 Million PLN | 42.5% |
| 2022 Q3 | 18.93 Million PLN | 76.16% |
| 2022 FY | 22.26 Million PLN | 263.93% |
| 2022 Q4 | 22.26 Million PLN | 17.61% |
| 2021 Q1 | 5.14 Million PLN | 50.85% |
| 2021 Q4 | 6.11 Million PLN | 25.63% |
| 2021 Q3 | 4.87 Million PLN | -3.05% |
| 2021 FY | 6.11 Million PLN | 79.41% |
| 2021 Q2 | 5.02 Million PLN | -2.35% |
| 2020 Q4 | 3.41 Million PLN | 0.0% |
| 2020 FY | 3.41 Million PLN | -50.23% |
| 2020 Q1 | - PLN | 0.0% |
| 2019 FY | 6.85 Million PLN | -29.37% |
| 2018 FY | 9.7 Million PLN | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioceltix S.A. | 2.26 Million PLN | -1644.75% |
| BIOTON S.A. | 215.86 Million PLN | 81.664% |
| Captor Therapeutics Spolka Akcyjna | 28.07 Million PLN | -40.988% |
| Mabion S.A. | 90.47 Million PLN | 56.253% |
| Molecure S.A. | 11.34 Million PLN | -248.894% |
| NanoGroup S.A. | 1.49 Million PLN | -2556.27% |
| Pharmena S.A. | 1.9 Million PLN | -1976.653% |
| Pure Biologics Spólka Akcyjna | 20.84 Million PLN | -89.882% |
| Ryvu Therapeutics S.A. | 120.36 Million PLN | 67.114% |
| Synthaverse S.A. | 153.26 Million PLN | 74.175% |
| Urteste S.A. | 1.85 Million PLN | -2033.747% |